BioVaxys study shows MVP-S vaccine combo boosts immune response and reduces ovarian tumor growth in mice.

BioVaxys Technology Corp. published a study demonstrating that their immunotherapeutic vaccine MVP-S, combined with a checkpoint inhibitor and low-dose cyclophosphamide, significantly reduces tumor volume and enhances immune cell presence in ovarian cancer mouse models. The study used MRI to track tumor and immune cell changes, supporting the potential of this combination therapy for treating epithelial ovarian cancer, a highly lethal gynecological cancer. This research aligns with ongoing clinical trials, including the PESCO trial, evaluating MVP-S with pembrolizumab and cyclophosphamide in recurrent ovarian cancer patients. The findings highlight the promise of combining immunotherapy and chemotherapy to improve treatment outcomes in ovarian cancer.